Clinical Trial: ctDNA-Informed Management of Early-Stage Rectal Cancer

U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07209215) titled 'ctDNA-Informed Management of Early-Stage Rectal Cancer' on Sept. 30.

Brief Summary: This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signatera Genome assay. The primary aims are to 1) assess pathologic complete response (path CR) in the ctDNA informed management arm; 2) assess pathologic complete response (path CR) in the post total neoadjuvant therapy (TNT) standard of care (SOC) surgery arm; and 3) assess disease free survival (DFS) in the ctDNA informed management arm.

Study Start Date: Nov., 2025

Study Type: INTERVENTIONAL ...